Medical Disorders
Resources
Basic InformationLookupsLatest News
FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12AHA News: Half of U.S. Adults Should Monitor Blood Pressure at Home, Study SaysWidely Prescribed Class of Meds Might Raise Dementia Risk9/11 Dust Linked to Prostate Cancer in First RespondersOcean Swimming Causes Skin Changes: StudyNew Drug Combats Leading Cause of DwarfismAHA News: What Migraine Sufferers Need to Know About Stroke RiskNorovirus Fears Stir Recall of Frozen BlackberriesFlying Insects in Hospitals Carry 'Superbug' GermsU.S. Cases of Infant Gut Illness Plummet After Vaccine IntroducedAHA News: This Faulty Gene May Help Predict Heart Muscle DiseaseCell Mapping Provides New Insights About AsthmaHealth Tip: Recognizing Balance DisordersThe Safer Way to Ease Post-Surgical PainSudden Death Can Occur Even in Well-Controlled EpilepsyStatins May Lower Risk of Stroke After Cancer RadiotherapyExperimental Drug Shows Early Promise Against Sickle Cell DiseaseVitamin D Supplements May Not Help Your HeartHow to Head Off a Pain in the NeckSprouts Supermarkets Recalls Frozen Spinach Due to Listeria FearsA-Fib Can Raise Dementia Risk, Even in Absence of StrokeAnother Climate Change Threat: More 'Flesh-Eating' Bacteria?Heading to Europe This Summer? Get Your Measles ShotAiling Heart Can Speed the Brain's Decline, Study FindsHealth Tip: Preventing GlaucomaHead Injuries Tied to Motorized Scooters Are Rising: StudyOverweight Kids Are at Risk for High Blood PressureHot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. CitiesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyHealth Tip: Early Signs of Lyme DiseaseHealth Tip: Hiccup Home Remedies
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Evenity Approved for Osteoporotic Women

HealthDay News
by -- Scott Roberts
Updated: Apr 9th 2019

TUESDAY, April 9, 2019 (HealthDay News) -- Evenity (romosozumab) injection has been approved by the U.S. Food and Drug Administration to treat osteoporosis in postmenopausal women at high risk of breaking a bone, the agency said Tuesday in a news release.

More than 10 million people in the U.S. have osteoporosis, making their thinning bones more likely to fracture, the FDA said. Most are women who have gone through menopause.

"Today's approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk," said Dr. Hylton Joffe, director of the agency's Division of Bone, Reproductive and Urologic Products. "But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it's important to carefully select patients for this therapy, which includes avoiding use in patients who have had a heart attack or stroke within the previous year."

Evenity is a monoclonal antibody that blocks the protein sclerostin and helps boost new bone formation. The drug's effectiveness drops after 12 doses, so no one should be given more than that amount, the FDA warned.

Evenity was evaluated in clinical trials involving more than 11,000 women with postmenopausal osteoporosis. The drug increased users' risk of cardiovascular death, heart attack and stroke, prompting the agency to require a boxed warning on the drug's label. Doctors should discontinue Evenity in any woman who has a heart attack or stroke during treatment, the FDA advised.

The most common side effects of Evenity included joint pain and headache.

The drug is produced by Amgen, based in Thousand Oaks, Calif.

More information

Learn more about this approval.




Facebook

Amazon Smile

To quit smoking, call Connecticut QuitLine at 1-800-QUIT-NOW.

Children and Adult services are available now with no wait time.  Please contact HBH Intake Department at 860-548-0101, option 2.

 


powered by centersite dot net